{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:59:25Z","timestamp":1787500765073,"version":"build-2736575974"},"reference-count":24,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Monoamine oxidase (MAO) inhibitors can interact with selective serotonin reuptake inhibitors (SSRIs)\/serotonin\u2013norepinephrine reuptake inhibitors (SNRIs). There is clinical interest surrounding use of ozanimod with SSRIs\/SNRIs because the major metabolites of ozanimod are weak inhibitors of MAO-B in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the incidence of treatment-emergent adverse events (TEAEs) potentially related to serotonin accumulation (SA) during concomitant ozanimod and SSRI\/SNRI use by performing analyses of data from an open-label, oral ozanimod 0.92 mg trial (DAYBREAK; NCT02576717).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>SA narrow (serotonin syndrome, neuroleptic malignant syndrome, and hyperthermia malignant) and broad (terms potentially associated with SA) MedDRA v24.0 searches were performed using TEAE data from participants with relapsing multiple sclerosis who entered DAYBREAK from phase 3 studies (cutoff February 1, 2022). Incidences of TEAEs matching terms from each search were stratified by SSRI\/SNRI use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 2257 DAYBREAK participants, 274 (12.1%) used an SSRI\/SNRI. No participants had TEAEs matching the SA narrow search terms. There was no significant difference in the percentage of participants with \u2a7e1 TEAE matching the SA broad search for those on versus off SSRIs\/SNRIs (on: 12.4%, n = 34\/274; off: 15.6%, n = 310\/1982, nominal p = 0.1630).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>MedDRA searches showed no increase in TEAEs potentially associated with SA with concomitant SSRI\/SNRI and ozanimod use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585231216854","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T01:07:18Z","timestamp":1703207238000},"page":"177-183","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-4283","authenticated-orcid":false,"given":"Robert T","family":"Naismith","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-9772","authenticated-orcid":false,"given":"Jeffrey A","family":"Cohen","sequence":"additional","affiliation":[{"name":"Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bar-Or","sequence":"additional","affiliation":[{"name":"Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-1054","authenticated-orcid":false,"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof W","family":"Selmaj","sequence":"additional","affiliation":[{"name":"Center for Neurology, \u0141\u00f3d\u017a, Poland"},{"name":"Collegium Medicum, Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich-Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia"},{"name":"Department of Neurology, Medical University of Vienna, Vienna, Austria"},{"name":"Palack\u00fd University Olomouc, Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K","family":"Sheffield","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Krakovich","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tatosian","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Reardon","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Khaychuk","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon V","family":"Riolo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Silva","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-2533","authenticated-orcid":false,"given":"Bruce AC","family":"Cree","sequence":"additional","affiliation":[{"name":"Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"bibr1-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.11.067"},{"key":"bibr2-13524585231216854","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.595584"},{"key":"bibr3-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2020.1782433"},{"key":"bibr4-13524585231216854","volume-title":"Selective serotonin reuptake inhibitors","author":"Chu A","year":"2022"},{"key":"bibr5-13524585231216854","volume-title":"Practice guideline for the treatment of patients with major depressive disorder","author":"Gelenberg AJ","year":"2010"},{"issue":"10","key":"bibr6-13524585231216854","first-page":"720","volume":"64","author":"Foong AL","year":"2018","journal-title":"Can Fam Physician"},{"key":"bibr7-13524585231216854","unstructured":"Zeposia (package insert). Princeton, NJ: Bristol Myers Squibb, 2023."},{"key":"bibr8-13524585231216854","unstructured":"Zeposia (summary of product characteristics). Utrecht: Celgene Distribution B.V. 2023."},{"key":"bibr9-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000220"},{"key":"bibr10-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01500-0"},{"key":"bibr11-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30238-8"},{"key":"bibr12-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30239-X"},{"key":"bibr13-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221102584"},{"key":"bibr14-13524585231216854","unstructured":"Common questions about trazodone\n                      . London: National Health Services, 2022."},{"key":"bibr15-13524585231216854","doi-asserted-by":"publisher","DOI":"10.4103\/aian.AIAN_344_18"},{"key":"bibr16-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.09088"},{"key":"bibr17-13524585231216854","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X13999150424113345"},{"key":"bibr18-13524585231216854","unstructured":"Lexapro (package insert). Irvine, CA: Allergan, 2017."},{"key":"bibr19-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.4.1070"},{"key":"bibr20-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.08.014"},{"key":"bibr21-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199710000-00006"},{"key":"bibr22-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1500"},{"issue":"3","key":"bibr23-13524585231216854","first-page":"196","volume":"71","author":"Aboukarr A","year":"2018","journal-title":"Can J Hosp Pharm"},{"key":"bibr24-13524585231216854","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300054"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231216854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585231216854","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231216854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:13:49Z","timestamp":1777695229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585231216854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1177\/13524585231216854"],"URL":"https:\/\/doi.org\/10.1177\/13524585231216854","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}